Precigen, Inc. (PGEN)
Market Cap | 376.11M |
Revenue (ttm) | 5.44M |
Net Income (ttm) | -96.91M |
Shares Out | 252.42M |
EPS (ttm) | -0.39 |
PE Ratio | n/a |
Forward PE | 9.14 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 776,268 |
Open | 1.540 |
Previous Close | 1.550 |
Day's Range | 1.440 - 1.540 |
52-Week Range | 0.840 - 1.880 |
Beta | 1.88 |
Analysts | Buy |
Price Target | 10.00 (+571.14%) |
Earnings Date | Aug 7, 2024 |
About PGEN
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gen... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 571.14% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/l/u/press10-2459076.jpg)
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
– Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; comple...
![](https://cdn.snapi.dev/images/v1/v/e/conf17-2446481.jpg)
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
![](https://cdn.snapi.dev/images/v1/k/d/press2-2430619.jpg)
Precigen Reports First Quarter 2024 Financial Results and Business Updates
– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation...
![](https://cdn.snapi.dev/images/v1/9/8/conf10-2419265.jpg)
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p...
![](https://cdn.snapi.dev/images/v1/q/k/conf2-2388396.jpg)
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
![](https://cdn.snapi.dev/images/v1/p/r/press8-2388131.jpg)
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
![](https://cdn.snapi.dev/images/v1/a/u/press10-2347238.jpg)
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HPV...
![](https://cdn.snapi.dev/images/v1/d/c/press1-2331833.jpg)
Precigen Reports Full Year 2023 Financial Results and Business Updates
– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second ...
![](https://cdn.snapi.dev/images/v1/b/g/press14-2320973.jpg)
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
![](https://cdn.snapi.dev/images/v1/j/f/conf7-2309579.jpg)
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
![](https://cdn.snapi.dev/images/v1/p/w/press3-2263093.jpg)
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
![](https://cdn.snapi.dev/images/v1/q/x/press12-2230329.jpg)
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla adenovec...
![](https://cdn.snapi.dev/images/v1/w/q/press13-2220212.jpg)
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
– PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; commer...
![](https://cdn.snapi.dev/images/v1/b/k/conf15-2200876.jpg)
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
![](https://cdn.snapi.dev/images/v1/w/q/press14-2176721.jpg)
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
GERMANTOWN, Md. , Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...
![](https://cdn.snapi.dev/images/v1/j/b/press8-2151330.jpg)
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval req...
![](https://cdn.snapi.dev/images/v1/4/b/press6-2145327.jpg)
Precigen to Participate in the Stifel 2023 Healthcare Conference
GERMANTOWN, Md. , Nov. 7, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
![](https://cdn.snapi.dev/images/v1/x/h/press7-2070075.jpg)
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
GERMANTOWN, Md. , Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...
![](https://cdn.snapi.dev/images/v1/f/1/press12-2014512.jpg)
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
– The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no additional randomized, placebo-controlled t...
![](https://cdn.snapi.dev/images/v1/1/0/press13-2014360.jpg)
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a BLA – – FDA a...
![](https://cdn.snapi.dev/images/v1/7/l/conf7-2005789.jpg)
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
GERMANTOWN, Md. , Aug. 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
![](https://cdn.snapi.dev/images/v1/a/i/press2-1940073.jpg)
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
– First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP – – Designation based on positive Phase...
![](https://cdn.snapi.dev/images/v1/j/u/press19-1921656.jpg)
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion and persistence when delivered via either ...
![](https://cdn.snapi.dev/images/v1/h/6/press20-1919799.jpg)
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade...
![](https://cdn.snapi.dev/images/v1/2/f/press3-1914044.jpg)
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer
– HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the US – – Current response rates to second line treat...